TY - JOUR
T1 - Topical application of phenytoin or nifedipine-loaded PLGA microspheres promotes periodontal regeneration in vivo
AU - Zhao, Xiao Heng
AU - Tay, Franklin R.
AU - Fang, Yan Jun
AU - Meng, Liu Yan
AU - Bian, Zhuan
N1 - Funding Information:
The authors deny any perceived or actual conflicts of interest. The present work was funded by National Natural Science Foundation of China ( 81470727 and 81571438 to Zhuan Bian and Liu-Yan Meng), National key research and development program ( 2016YFC1000505 ) and Hubei Province’s Outstanding Medical Academic Leader Program to Zhuan Bian, and Applied Basic Research Program of Wuhan, China ( 2014062801011267 ) to Liu-Yan Meng. The authors thank Mr. Zhi-Yong Chen for animal technical support, Ms. Han-Ping Li for histological specimen preparation, Mr. Jian-She He for technical guidance in the HPLC assay and Ms. Qian Gao for her help in the animal experiment. The authors thank Dentsply Sirona Inc. (China) for providing a plugger to simplify the process of drug delivery.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2019/1
Y1 - 2019/1
N2 - Objectives: Gingival recession and alveolar bone loss are common manifestations of periodontitis. Periodontal regeneration is the ideal strategy for rehabilitating periodontal tissue defects and preventing tooth loss. The present study examined whether localized, topical application of gingival overgrowth-inducing drugs, phenytoin, nifedipine or cyclosporine, induces periodontal regeneration. Methods: Polylactic-co-glycolic acid (PLGA) was used as the carrier for preparation of phenytoin, nifedipine or cyclosporine-loaded PLGA microspheres, using an oil-in-water emulsification technique. The drug-loaded microspheres were delivered to periodontal defects created on alveolar ridges mesial to the first maxillary molars of Sprague-Dawley rats. After eight weeks, the operation area in each rat, including the maxillary molars and periodontal tissues, was harvested and evaluated by micro-computed tomography, histochemical and immunohistochemical analyses. Results: Physical parameters representative of periodontal regeneration, including the length of new alveolar bone (p < 0.01) and the area of new alveolar bone (p < 0.01) were significantly improved in the phenytoin group. Compared to other groups, the phenytoin group demonstrated increased expression of COL-1, VEGF-A, osteoblast and osteoclast markers (BMP-2, TGF-β1, OCN and TRAP staining), as well as decreased expression of MMP-8. Conclusions: Results of the present study provided new evidence that localized, controlled release of phenytoin confers therapeutic benefits toward gingival recession and alveolar bone loss. Phenytoin appears to be a promising drug that promotes periodontal regeneration.
AB - Objectives: Gingival recession and alveolar bone loss are common manifestations of periodontitis. Periodontal regeneration is the ideal strategy for rehabilitating periodontal tissue defects and preventing tooth loss. The present study examined whether localized, topical application of gingival overgrowth-inducing drugs, phenytoin, nifedipine or cyclosporine, induces periodontal regeneration. Methods: Polylactic-co-glycolic acid (PLGA) was used as the carrier for preparation of phenytoin, nifedipine or cyclosporine-loaded PLGA microspheres, using an oil-in-water emulsification technique. The drug-loaded microspheres were delivered to periodontal defects created on alveolar ridges mesial to the first maxillary molars of Sprague-Dawley rats. After eight weeks, the operation area in each rat, including the maxillary molars and periodontal tissues, was harvested and evaluated by micro-computed tomography, histochemical and immunohistochemical analyses. Results: Physical parameters representative of periodontal regeneration, including the length of new alveolar bone (p < 0.01) and the area of new alveolar bone (p < 0.01) were significantly improved in the phenytoin group. Compared to other groups, the phenytoin group demonstrated increased expression of COL-1, VEGF-A, osteoblast and osteoclast markers (BMP-2, TGF-β1, OCN and TRAP staining), as well as decreased expression of MMP-8. Conclusions: Results of the present study provided new evidence that localized, controlled release of phenytoin confers therapeutic benefits toward gingival recession and alveolar bone loss. Phenytoin appears to be a promising drug that promotes periodontal regeneration.
KW - Alveolar bone loss
KW - Anti-epileptics
KW - Bone remodeling
KW - Drug delivery
KW - Gingival overgrowth
UR - http://www.scopus.com/inward/record.url?scp=85054844676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054844676&partnerID=8YFLogxK
U2 - 10.1016/j.archoralbio.2018.10.002
DO - 10.1016/j.archoralbio.2018.10.002
M3 - Article
C2 - 30342306
AN - SCOPUS:85054844676
SN - 0003-9969
VL - 97
SP - 42
EP - 51
JO - Archives of Oral Biology
JF - Archives of Oral Biology
ER -